Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Watson Fentanyl Buccal Tablets Get FDA Tentative Approval
Watson’s Fentanyl Citrate Buccal tablets are a generic version of Cephalon’s Fentora. Fentora is used to treat breakthrough pain in cancer patients who are taking regularly scheduled doses
Watson’s Fentanyl Citrate Buccal tablets are a generic version of Cephalon’s Fentora. Fentora is used to treat breakthrough pain in cancer patients who are taking regularly scheduled doses
By providing Pariet as a new treatment option for non-erosive GERD in Japan, Eisai seeks to make further contributions to the treatment of patients with acid-related diseases in
In the trial, all 14 patients were found to have circulating interferon Alpha-2b levels below the bioassay’s lower limit of detection (6.25 pg/mL) at all sampling time points.
The worldwide suspension of the program, which is effective immediately, follows a small number of reports of Pfizer Tanezumab patients experiencing the worsening of osteoarthritis leading to joint
The second license agreement provides GSK with access to BioWa’s Complegent Technology for enhancing the complement-dependent cytotoxicity (CDC) of select GSK therapeutic antibodies. These two technologies may be
Takeda is now aiming to increase its global market coverage to approximately 90% by the end of fiscal 2012, one of the key strategic initiatives of the 2010-2012
As per the agreement, OMJPI is expected to get an exclusive worldwide license to manufacture, develop and commercialise several Metabolex programs which are currently at the preclinical stage.
Probactive Biotech said that it has combined medical-grade Iodine-131 and Yttrium-90 with antitumor antibodies, producing targeted anticancer activity. The parts of the research and development program is expected
Lucentis is a vascular endothelial growth factor (VEGF) inhibitor which was first approved by the FDA for the treatment of neovascular (wet) age-related macular degeneration (AMD) in 2006.
Beta-lactam antibiotics represent a class of drugs with a wide spectrum of antibacterial activity. Hospira said that Meropenem represents the first US drug launch from its recent acquisition